Cohen Investment Advisors LLC Acquires 10,097 Shares of Pfizer Inc. (NYSE:PFE)

Cohen Investment Advisors LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.9% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 88,506 shares of the biopharmaceutical company's stock after purchasing an additional 10,097 shares during the quarter. Cohen Investment Advisors LLC's holdings in Pfizer were worth $2,243,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Brighton Jones LLC raised its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Pfizer by 47.8% during the 4th quarter. Victory Capital Management Inc. now owns 5,152,861 shares of the biopharmaceutical company's stock valued at $136,705,000 after acquiring an additional 1,666,189 shares in the last quarter. Granite FO LLC lifted its position in shares of Pfizer by 8.6% in the 4th quarter. Granite FO LLC now owns 24,242 shares of the biopharmaceutical company's stock worth $643,000 after buying an additional 1,915 shares during the last quarter. Finally, Vision Financial Markets LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $283,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.6%

Shares of NYSE:PFE traded down $0.15 during midday trading on Monday, hitting $25.23. 34,892,825 shares of the stock were exchanged, compared to its average volume of 41,695,614. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The business's fifty day simple moving average is $23.72 and its two-hundred day simple moving average is $24.81. The company has a market capitalization of $143.44 billion, a PE ratio of 18.28, a P/E/G ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the previous year, the company earned $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.82%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group raised their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Bank of America boosted their price objective on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. TD Cowen decreased their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. Finally, Leerink Partners dropped their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.